Table 3.
Antimicrobial Drug Susceptibility of Seven Shewanella xiamenensis*
| Isolates | MIC (mg/L) and Interpretation | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMP | PIP | AMC | SAM | TZP | IPM | MEM | CZ | FEP | CTX | CAZ | ATM | CL | C | TE | SXT | AMK | GEN | CIP | LEV | MXF | |
| HD6416 | >16 | >64 | 16/8 | >16/8 | >64/4 | >8 | >8 | >16 | >16 | >32 | >16 | ≤2 | ≤0.5 | >16 | ≤2 | >2/38 | ≤8 | >8 | ≤0.5 | ≤1 | ≤1 |
| HD6420 | >16 | >64 | 16/8 | >16/8 | >64/4 | >8 | >8 | >16 | >16 | >32 | >16 | ≤2 | ≤0.5 | ≤4 | 4 | >2/38 | ≤8 | >8 | >2 | ≤1 | ≤1 |
| HD6424 | >16 | >64 | 16/8 | >16/8 | 16/4 | >8 | >8 | >16 | 16 | >32 | >16 | ≤2 | ≤0.5 | 16 | ≤2 | >2/38 | ≤8 | >8 | ≤0.5 | ≤1 | ≤1 |
| HD6443 | >16 | >64 | >16/8 | >16/8 | >64/4 | >8 | >8 | >16 | >16 | >32 | >16 | >16 | ≤0.5 | >16 | ≤2 | >2/38 | ≤8 | >8 | >2 | 2 | ≤1 |
| HD6446 | >16 | 8 | 16/8 | >16/8 | 64/4 | >8 | >8 | >16 | >16 | >32 | >16 | ≤2 | ≤0.5 | ≤4 | 4 | >2/38 | ≤8 | >8 | >2 | 4 | 2 |
| HD6449 | >16 | 64 | 16/8 | >16/8 | 8/4 | >8 | >8 | >16 | >16 | >32 | >16 | ≤2 | ≤0.5 | ≤4 | 8 | >2/38 | ≤8 | >8 | >2 | 2 | 2 |
| HD6452 | >16 | >64 | 16/8 | >16/8 | 8/4 | >8 | >8 | >16 | 8 | >32 | >16 | ≤2 | 1 | ≤4 | 8 | >2/38 | ≤8 | >8 | >2 | 2 | 2 |
Notes: *Antimicrobial susceptibility testing was performed on Phoenix M50 Automated System (BD, USA). And the breakpoint was interpreted by the “Other Non-Enterobacterales” criteria: blank: no reference breakpoint; light gray: susceptible; medium gray: intermediate; dark gray: resistant.
Abbreviations: AMP, ampicillin; PIP, piperacillin; AMC, amoxicillin-clavulanate; SAM, ampicillin-sulbactam; TZP, piperacillin-tazobactam; IPM, imipenem; MEM, meropenem; CZ, cefazolin; FEP, cefepime; CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; C, chloramphenicol; CL, colistin; TE, tetracycline; SXT, trimethoprim-sulfamethoxazole; AN, amikacin; GM, gentamycin; CIP, ciprofloxacin; LVX, levofloxacin; MXF, moxifloxacin.